ImmuCell Corporation

Stage 3 · Topping · week 5

As of Oct 22, 2026, ImmuCell is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $10.44, 10.9% below its 52-week high and above its 200-day average, which is rising.

$10.44

-0.76% today

$94.8M · Micro cap

Market Neutral — Fading

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is ICCC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 26w

S2 17w

S3 14w

S2 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 11w → S1 4w → S4 8w → S1 4w → S2 8w → S3 6w → S4 26w → S1 5w → S2 12w → S3 4w → S2 17w → S3 14w → S4 7w → S1 3w → S2 31w → S3 5w current

Total tracked: 166 weeks across 17 stage runs.

ICCC among Biotechnology68th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…68	ICCCImmuCell Corporation	Stage 3 · wk 5	91	+4.5%

vs 52W High

-10.9%

$4.56 lo$11.72 hi

10.9% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

19.3%

200 DMA: $8.75 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.30x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↗ ⇈

Short-term trend rising gently, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+4.5%

-5.3%

+30.5%

YTD

+76.4%

+70.3%

Scan Membership

Breakout Watch

Latest: 2025-01-10

8 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.30x

2026-10-21S3

Wk 5 · Vol 0.34x

2026-10-20S3

Wk 5 · Vol 0.21x

2026-10-19S3

Wk 5 · Vol 0.33x

2026-10-16S3

Wk 4 · Vol 0.14x

2026-10-15S3

Wk 4 · Vol 0.47x

2026-10-14S3

Wk 4 · Vol 0.44x

2026-10-13S3

Wk 4 · Vol 2.45x

2026-10-12S3

Wk 4 · Vol 0.55x

2026-10-09S3

Wk 3 · Vol 0.09x

2026-10-08S3

Wk 3 · Vol 0.24x

2026-10-07S3

Wk 3 · Vol 0.24x

Moving averages & range

50 DMA

$10.01

200 DMA

$8.75

52W High

$11.72

52W Low

$4.56

5D Low

$10.44

Resistance levels (recent highs)

20d High

$10.79

60d High

$11.21

120d High

$11.72

250d High

$11.72

Next resistance

+3.4%

to 20d High

P/E (TTM)

149.1

Forward -94.9

Earnings Growth (YoY)

+259.9%

Revenue +11.5%

ROE

+2.6%

Profit margin +2.6%

Dividend Yield

0.00%

P/B 3.0

ImmuCell: quick answers

What stage is ImmuCell in?

As of Oct 22, 2026, ImmuCell (ICCC) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean

Is ImmuCell in an uptrend?

Its uptrend has stalled. ImmuCell is in Stage 3, the topping phase that follows an advance. It trades 19.3% above its 200-day average, which is rising.

How far is ImmuCell from its 52-week high?

ImmuCell closed at $10.44 on Oct 22, 2026, 10.9% below its 52-week high of $11.72. Its 52-week low is $4.56.

How has ImmuCell performed over the past year?

As of Oct 22, 2026, ImmuCell is up 70.3% over the past year and up 76.4% so far in 2026.

Which sector and industry is ImmuCell in?

ImmuCell is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.